2. Immunology/Inflammation Apoptosis
  3. COX Apoptosis
  4. Deracoxib

Deracoxib  (Synonyms: SC 046; SC 46; SC 59046)

Cat. No.: HY-17509 Purity: 99.65%
COA
SDS
Handling Instructions Technical Support

Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

For research use only. We do not sell to patients.

Deracoxib

Deracoxib Chemical Structure

CAS No. : 169590-41-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Deracoxib:

Deracoxib Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Deracoxib

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas[1][2][3][4][5].

IC50 & Target[1]

COX-2

 

In Vitro

Deracoxib (0-1000 μM, 72 h) inhibits the growth of osteosarcoma cell lines (POS, HMPOS and COS31) (IC50s ranged from 70 to 150 μM) and CMT-U27 cells (IC50 = 974.481 μM)[1][2].
Deracoxib (100-250 μM, 72 h) causes fragmentation of osteosarcoma cells and loss of their ability to adhere to the surface, while it only leads to a reduction in the number of fibroblasts, with the cells maintaining normal morphology[1].
Deracoxib (50-1000 μM, 72 h) induces G0/G1 phase arrest and cell apoptosis in CMT-U27 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Deracoxib Related Antibodies

Apoptosis Analysis[2]

Cell Line: CMT-U27 cells
Concentration: 250, 500, 1000 μM
Incubation Time: 72 h
Result: Significantly increased the proportion of apoptotic cells.

Cell Cycle Analysis[2]

Cell Line: CMT-U27 cells
Concentration: 50, 100, 250, 500 and 1000 μM
Incubation Time: 72 h
Result: Caused G0/G1 phase arrest at high concentrations (500-1000 μM).
In Vivo

Deracoxib (1-2 mg/kg, p.o., 1 dose before and 2 doses after the operation, for 3 days) has a significant therapeutic effect on pain control after soft tissue surgery in dogs[3].
Deracoxib (3 mg/kg, p.o., once daily until progressive disease progresses) is generally well tolerated by dogs and had antitumor activity against transitional cell carcinoma (TCC)[4].
Deracoxib (15 mg/kg, p.o., twcie daily for 26 days) prevents disease in murine Collagen (HY-NP010) induced arthritis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

397.37

Formula

C17H14F3N3O3S
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC)C(F)=C3)C=C1)(N)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (125.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5165 mL 12.5827 mL 25.1655 mL
5 mM 0.5033 mL 2.5165 mL 5.0331 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5165 mL 12.5827 mL 25.1655 mL 62.9137 mL
5 mM 0.5033 mL 2.5165 mL 5.0331 mL 12.5827 mL
10 mM 0.2517 mL 1.2583 mL 2.5165 mL 6.2914 mL
15 mM 0.1678 mL 0.8388 mL 1.6777 mL 4.1942 mL
20 mM 0.1258 mL 0.6291 mL 1.2583 mL 3.1457 mL
25 mM 0.1007 mL 0.5033 mL 1.0066 mL 2.5165 mL
30 mM 0.0839 mL 0.4194 mL 0.8388 mL 2.0971 mL
40 mM 0.0629 mL 0.3146 mL 0.6291 mL 1.5728 mL
50 mM 0.0503 mL 0.2517 mL 0.5033 mL 1.2583 mL
60 mM 0.0419 mL 0.2097 mL 0.4194 mL 1.0486 mL
80 mM 0.0315 mL 0.1573 mL 0.3146 mL 0.7864 mL
100 mM 0.0252 mL 0.1258 mL 0.2517 mL 0.6291 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Deracoxib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Deracoxib169590-41-4SC 046 SC 46 SC 59046SC046SC-046SC46SC 46SC-46SC59046SC 59046SC-59046COXApoptosisCyclooxygenaseLeukotrieneProstaglandinCOX-1/25-LOXAnimal models of RAInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Deracoxib
Cat. No.:
HY-17509
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.